Intratumoral activation of the complement cascade may have therapeutic potential in patients with lung cancer with strong EGFR signaling, shows a new study. EGFR-triggered expression of CD55 and CD59 prevents opsonization of tumor cells, inhibits antitumor immunity and confers resistance to immune-checkpoint inhibitors.
This is a preview of subscription content, log in via an institution to check access.
References
Shao, F. et al. Nat. Cancer https://doi.org/10.1038/s43018-022-00444-4 (2022).
Roumenina, L. T., Daugan, M. V., Petitprez, F., Sautes-Fridman, C. & Fridman, W. H. Nat. Rev. Cancer 19, 698–715 (2019).
Hsu, Y. F. et al. Mol. Cancer 9, 139 (2010).
Patil, N. S. et al. Cancer Cell 40, 289–300 e4 (2022).
Meylan, M. et al. Immunity 55, 527–541 e5 (2022).
Ajona, D. et al. J. Natl Cancer Inst. 105, 1385–1393 (2013).
Kwak, J. W. et al. Cancer Res. 78, 143–156 (2018).
Ajona, D. et al. Cancer Discov. 7, 694–703 (2017).
Midha, A., Dearden, S. & McCormack, R. Am. J. Cancer Res. 5, 2892–2911 (2015).
To, K. K. W., Fong, W. & Cho, W. C. S. Front. Oncol. 11, 635007 (2021).
Madeddu, C. et al. Int. J. Mol. Sci. 23, 6489 (2022).
Daugan, M. V. et al. Cancer Immunol. Res. 9, 909–925 (2021).
Golec, E. et al. Proc. Natl Acad. Sci. USA 119, e2120083119 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Roumenina, L.T., Cremer, I. COMPLEMENTing immunotherapy. Nat Cancer 3, 1144–1146 (2022). https://doi.org/10.1038/s43018-022-00442-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-022-00442-6
- Springer Nature America, Inc.